Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys plus Ribavirin in Methadone Maintenance Patients
NCT00087594Phase 4Completed
- Sponsor
- Roche
- Start
- Nov 2003
- Primary completion
- Oct 2006
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (2 arms), sponsored by Roche. Primary endpoint: Number of Participants With Treatment Completion Rate (TCR) at 48 weeks. Started Nov 2003; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00087594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087594.